Parkinson's Disease: Difference between revisions
Cleaned up the references. |
No edit summary |
||
| Line 3: | Line 3: | ||
[[Image:Parkinsons patients have less dopamine.png|right|Dopamine in Parkinson's Disease]] | [[Image:Parkinsons patients have less dopamine.png|right|Dopamine in Parkinson's Disease]] | ||
In the later stages, mental and behavioural | In the later stages, mental and behavioural symptoms may occur such as anxiety, depression, anosmis, difficultly sleeping and even things such as dementia. | ||
The main 4 dopaminergic pathways are:- | The main 4 dopaminergic pathways are:- | ||
| Line 19: | Line 19: | ||
=== References === | === References === | ||
<references /><br> | <references /><ref>http://www.nhs.uk/Conditions/Parkinsons-disease/Pages/Introduction.aspx</ref><br> | ||
Revision as of 17:15, 4 December 2016
Parkinson’s disease, also known as hypokinetic rigid syndrome (HRS), is an idiopathic and has no known cause. It is normally due to the degeneration of dopaminergic neurones of the nigrostriatal tract and loss of dopamine (DA) neurotransmission in the striatum. The symptoms of this disease are a resting tremor, muscle rigidity, suppression of voluntary movements (hypokinesis) and postural instability. Another common symptom of parkinsons disease is freezing which is the inability to move temporarily and can last a few seconds to several minutes. Often people feel like their feet are stuck to the ground and this occurs often when a sufferer is carrying out repetitive movements like walking, eating or writing.
In the later stages, mental and behavioural symptoms may occur such as anxiety, depression, anosmis, difficultly sleeping and even things such as dementia.
The main 4 dopaminergic pathways are:-
- Nigrostriatal - Substantia nigra to striatum
- Striatum Mesolimbic - Ventral tegmental area to nucleus accumbens
- Mesocortical - Ventral tegmental area to frontal cortex
- Frontal cortex Tuberoinfundibular - Arcuate nucleus to pituitary gland
The decarboxylase inhibitor – carbidopa, the </span>MAO inhibitor: Selegiline and D2 receptor agonists like Bromocriptine can be used to treat Parkinson’s disease.
L-DOPA is a drug often given to patients in early stages of parkinsons disease to suppress symptoms. L-DOPA is converted to dopamine in the brain therefore increasing the amount available to bind to dopamine receptors[1].
References
- ↑ Picture reference: Parkinsons Disease. National Institue of Environmental Health Sciences. Available from: http://www.niehs.nih.gov/health/topics/conditions/parkinson/